Explore more publications!

Health Observer Bermuda: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Observer Bermuda.

Press releases published on January 13, 2026

Aqua free startet mit „Shower2go“ in den B2C-Markt: Mobile Reisedusche für sicheres Duschen ohne Legionellen für unterwegs
Aqua free enters the B2C market with “Shower2go”: a portable travel shower for safer showering on the go – helping to reduce exposure to Legionella
Dentsply Sirona and Benco Dental Announce Expanded Partnership to Include Dental Technology Solutions
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
Voting Rights and Shares Capital of the Company
Information mensuelle relative au nombre total de droits de vote  et d’actions composant le capital social
Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
INVO Fertility to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Kaneka Medical America LLC Announces U.S. Launch of WaveSelect 1014 Guidewire
Southern Pain and Spine Specialists Announces Dr. Ammar Alamarie, MD Named Castle Connolly Top Doctor for Pain Management in 2025 for Second Consecutive Year
OC WASTE & RECYCLING PARTNERS WITH AGROMIN TO EXPAND  COMPOST AND MULCH PROGRAM
The Ebony Canal Scores NAACP Image Award Nomination for Outstanding Short Form Documentary
Metabo Drops Examined: Is It Legit for Weight Loss? Safety Checks and Consumer Analysis 2026
La FDA américaine accorde la désignation  « Breakthrough Therapy » à l’IPN60340 (ICT01) d’Ipsen dans la leucémie myéloïde aiguë de première ligne chez les patients inéligibles à une chimiothérapie intensive
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
Blue Cross and Blue Shield of Minnesota Adds Virtual Primary Care from Doctor On Demand to Provider Network

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions